276 related articles for article (PubMed ID: 32539491)
1. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Nasri F; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
Expert Opin Drug Saf; 2020 Aug; 19(8):1031-1040. PubMed ID: 32539491
[TBL] [Abstract][Full Text] [Related]
2. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
[TBL] [Abstract][Full Text] [Related]
5. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
Feifel D; Malcolm B; Boggie D; Lee K
J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic and Safety Outcomes of Intravenous Ketamine for Treatment-refractory Depression in a Veteran Population: A Case Series.
Vitek G; Langenfeld R; Walters RW; Elson A; Driscoll D; Ramaswamy S
Mil Med; 2023 Jul; 188(7-8):e2242-e2248. PubMed ID: 36539918
[TBL] [Abstract][Full Text] [Related]
10. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
McIntyre RS; Rosenblat JD; Rodrigues NB; Lipsitz O; Chen-Li D; Lee JG; Nasri F; Subramaniapillai M; Kratiuk K; Wang A; Gill H; Mansur RB; Ho R; Lin K; Lee Y
Psychiatry Res; 2021 Aug; 302():113993. PubMed ID: 34034067
[TBL] [Abstract][Full Text] [Related]
11. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
[TBL] [Abstract][Full Text] [Related]
12. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
13. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
[TBL] [Abstract][Full Text] [Related]
14. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
[TBL] [Abstract][Full Text] [Related]
15. Ketamine for the treatment of depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
[TBL] [Abstract][Full Text] [Related]
16. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Shekotikhina M; Vinberg M; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
J Affect Disord; 2021 Mar; 282():160-164. PubMed ID: 33418362
[TBL] [Abstract][Full Text] [Related]
17. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of ketamine response in treatment-resistant major depression.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
Zhou YL; Liu WJ; Wang CY; Zheng W; Lan XF; Weng SY; Ning YP
J Psychopharmacol; 2021 Feb; 35(2):159-167. PubMed ID: 32720857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
